A price war has hit India’s weight-loss and diabetes drug market after semaglutide lost patent protection, pushing innovator Novo Nordisk to cut prices of Ozempic and Wegovy. Cheaper generics may widen access, but concerns over misuse are rising, prompting regulatory scrutiny.
Mint Explainer: What the weight-loss drug frenzy means for pharma sector and for you
